1. Company Information

Incorporated in 1999, Rubicon Research Limited is a pharmaceutical company engaged in the development, manufacturing, and commercialization of differentiated formulations. As of June 30, 2025, Rubicon Research had a portfolio of 72 active Abbreviated New Drug Application (ANDA) and New Drug Application (NDA) products approved by the US FDA. The company’s portfolio includes 66 commercialized products, with a US generic pharmaceutical market size of USD 2,455.7 million, of which Rubicon Research Limited contributed USD 195 million in Fiscal 2024. Company Commercialized Products in CNS and CVS therapy areas contributed 46.13% and 38.48% of our revenue from operations in the three month periods ended June 30, 2025 and 2024, respectively, and 41.85%, 40.71% and 38.08% of our revenue from operations in Fiscals 2025, 2024 and 2023, respectively. Company jointly developed Raldesy® with its NDA holder and hold an exclusive worldwide license for its commercialization while the NDA is held by the third-party joint developer. Equetro® and Raldesy® are promoted to prescribers via personal and non-personal promotion methods.

2. Competitive Strengths

1) Fastest-growing Indian pharmaceutical company amongst peers.
2) Data-driven product selection framework
3) Strong R&D capabilities
4) Robust sales and distribution capabilities in the US
5) Strong track record of compliance combined with expertise in cost effective manufacturing
6) Experienced and entrepreneurial management team

3. Rubicon Research IPO Registrar

MUFG Intime India Pvt.Ltd.

Phone:+91-22-4918 6270
Email: rubicon.ipo@linkintime.co.in
Website:   https://linkintime.co.in